unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Company profile
Ticker
EDIT
Exchange
Website
CEO
Cynthia Collins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Editas Medicine, LLC • Editas Securities Corporation ...
EDIT stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
S-3ASR
Automatic shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
28 Feb 24
8-K
Regulation FD Disclosure
13 Dec 23
8-K
Regulation FD Disclosure
11 Dec 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
Transcripts
EDIT
Earnings call transcript
2023 Q4
28 Feb 24
EDIT
Earnings call transcript
2023 Q3
3 Nov 23
EDIT
Earnings call transcript
2023 Q2
2 Aug 23
EDIT
Earnings call transcript
2023 Q1
5 May 23
EDIT
Earnings call transcript
2022 Q4
22 Feb 23
EDIT
Earnings call transcript
2022 Q3
2 Nov 22
EDIT
Earnings call transcript
2022 Q2
4 Aug 22
EDIT
Earnings call transcript
2022 Q1
4 May 22
EDIT
Earnings call transcript
2021 Q4
24 Feb 22
EDIT
Earnings call transcript
2021 Q3
8 Nov 21
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Erick Lucera
5 Mar 24
4
Linda Burkly
5 Mar 24
4
Gilmore Neil O'Neill
5 Mar 24
4
Baisong Mei
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
10 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 86.42 mm | 86.42 mm | 86.42 mm | 86.42 mm | 86.42 mm | 86.42 mm |
Cash burn (monthly) | 46.09 mm | 10.68 mm | 16.72 mm | 17.39 mm | 11.82 mm | 12.68 mm |
Cash used (since last report) | 307.55 mm | 71.27 mm | 111.57 mm | 116.02 mm | 78.87 mm | 84.63 mm |
Cash remaining | -221.14 mm | 15.15 mm | -25.15 mm | -29.61 mm | 7.55 mm | 1.78 mm |
Runway (months of cash) | -4.8 | 1.4 | -1.5 | -1.7 | 0.6 | 0.1 |
Institutional ownership, Q3 2023
74.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 214 |
Opened positions | 26 |
Closed positions | 41 |
Increased positions | 75 |
Reduced positions | 61 |
13F shares | Current |
---|---|
Total value | 474.14 bn |
Total shares | 61.01 mm |
Total puts | 252.30 k |
Total calls | 390.60 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 8.54 mm | $66.58 bn |
BLK Blackrock | 8.16 mm | $63.65 bn |
Deep Track Capital | 7.10 mm | $55.40 bn |
STT State Street | 5.77 mm | $45.01 bn |
Woodline Partners | 3.26 mm | $25.43 bn |
Marshall Wace | 2.19 mm | $17.12 bn |
Geode Capital Management | 1.81 mm | $14.10 bn |
Pictet Asset Management Holding | 1.80 mm | $14.04 bn |
Dimensional Fund Advisors | 1.70 mm | $13.27 bn |
MS Morgan Stanley | 1.33 mm | $10.41 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Gilmore Neil O'Neill | Common Stock | Sell | Dispose S | No | No | 9.4172 | 77,824 | 732.88 k | 327,470 |
4 Mar 24 | Baisong Mei | Common Stock | Sell | Dispose S | No | No | 9.4173 | 20,327 | 191.43 k | 141,543 |
2 Mar 24 | Linda Burkly | Common Stock | Grant | Acquire A | No | No | 0 | 15,055 | 0.00 | 85,022 |
2 Mar 24 | Linda Burkly | Common Stock | Grant | Acquire A | No | No | 0 | 24,800 | 0.00 | 69,967 |
2 Mar 24 | Linda Burkly | Stock Option (right to buy) Common Stock | Grant | Acquire A | No | No | 10.53 | 74,400 | 783.43 k | 74,400 |
2 Mar 24 | Erick Lucera | Common Stock | Grant | Acquire A | No | No | 0 | 25,966 | 0.00 | 139,166 |
2 Mar 24 | Erick Lucera | Common Stock | Grant | Acquire A | No | No | 0 | 35,300 | 0.00 | 113,200 |
2 Mar 24 | Erick Lucera | Stock Option (right to buy) Common Stock | Grant | Acquire A | No | No | 10.53 | 106,000 | 1.12 mm | 106,000 |
2 Mar 24 | Gilmore Neil O'Neill | Common Stock | Grant | Acquire A | No | No | 0 | 72,212 | 0.00 | 405,294 |
2 Mar 24 | Gilmore Neil O'Neill | Common Stock | Grant | Acquire A | No | No | 0 | 72,213 | 0.00 | 333,082 |
News
The Latest Analyst Ratings For Editas Medicine
29 Feb 24
Citigroup Maintains Buy on Editas Medicine, Raises Price Target to $16
29 Feb 24
Barclays Maintains Equal-Weight on Editas Medicine, Raises Price Target to $11
29 Feb 24
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
28 Feb 24
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
28 Feb 24